Stringer, E., Bohnsack, J., Bowyer, S. L., Griffin, T. A., Huber, A. M., Lang, B., Lindsley, C. B., Ota, S., Pilkington, C., Reed, A. M., Scuccimarri, R., Feldman, B. M. (2010).
Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.
Ruperto, N., Pistorio, A., Ravelli, A., Rider, L. G., Pilkington, C., Oliveira, S., Wulffraat, N., Espada, G., Garay, S., Cuttica, R., Hofer, M., Quartier, P., Melo-Gomes, J., Reed, A. M., Wierzbowska, M., Feldman, B. M., Harjacek, M., Huppertz, H. I., Nielsen, S., Flato, B., Lahdenne, P., Michels, H., Murray, K. J., Punaro, L., Rennebohm, R., Russo, R., Balogh, Z., Rooney, M., Pachman, L. M., Wallace, C., Hashkes, P., Lovell, D. J., Giannini, E. H., Gare, B. A., Martini, A. (2010).
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. A Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).
Li, C. K., Knopp, P., Moncrieffe, H., Singh , B., Shah S., K Nagaragu, K. Varsani, H., Gao, B., and Wedderburn. L. R. (2009).
Over expression of MHC class l heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis.
Gunawardena,H., Wedderburn,L.R., Chinoy,H., Betteridge,Z.E., North,J., Ollier,W.E.R., Cooper,R.G., Oddis,C.V., Ramanan,A.V., Davidson,J.E., Mchugh,N.J. (2009).
Autoantibodies to a 140-kd Protein in Juvenile Dermatomyositis Are Associated With Calcinosis.
Chinoy,H., PayneD., Poulton,K., Fertig,N., Betteridge,Z., Gunawardena,H., Davidson,J. E., Oddis,C. Wedderburn,L.R., McHugh,N.J., Ollier,W. E., Cooper R. G (2009).
HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy.
Apaz MT, Saad-Magalhães C, Pistorio A, Ravelli A, de Oliveira Sato J, Marcantoni MB, Meiorin S, Filocamo G, Pilkington C, Maillard S, et al. (2009).
Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.
Salomonsson, S., Grundtman, C., Zhang, S-J., Lanner, J., Li, C., Katz, A., Wedderburn L. R., Kanneboyina N., and Lundberg, I.E. (2009).
Up-regulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle.
Chinoy, H., Platt H., Lamb, J. A., Z. Betteridge, Z., Gunawardena H., Fertig, N., Varsani, H., Davidson, J. Oddis, C. V., McHugh, N. J., Wedderburn, L. R., Ollier, W. E. R., and Cooper R. G., UK Adult Onset Myositis Immunogenetic Collaboration and the Juvenile Dermatomyositis Research Group. (2008).
The PTPN22 gene is associated with juvenile and adult UK Caucasian idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype.